Journal: Journal of Clinical Microbiology

Article Title: Performance of Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussis ▿

doi: 10.1128/JCM.01371-10

Figure Lengend Snippet: Composition of commercial ELISAs and intra-assay variation of IgG antibodies to pertussis antigens

Article Snippet: Virotech , Pertussis Toxin IgG/IgA , PT , IgG/IgA , Arbitrary VE/ml , 5 , 1.

Techniques: Intra Assay, Enzyme-linked Immunosorbent Assay

Journal: Journal of Clinical Microbiology

Article Title: Performance of Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussis ▿

doi: 10.1128/JCM.01371-10

Figure Lengend Snippet: Diagnostic algorithm for evaluation of anti-PT IgG in patient sera.

Article Snippet: Virotech , Pertussis Toxin IgG/IgA , PT , IgG/IgA , Arbitrary VE/ml , 5 , 1.

Techniques: Diagnostic Assay

Journal: Journal of Clinical Microbiology

Article Title: Performance of Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussis ▿

doi: 10.1128/JCM.01371-10

Figure Lengend Snippet: Linearity of anti-PT IgG concentrations as measured by ELISA kits and compared to expected values of reference preparations.

Article Snippet: Virotech , Pertussis Toxin IgG/IgA , PT , IgG/IgA , Arbitrary VE/ml , 5 , 1.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Journal of Clinical Microbiology

Article Title: Performance of Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussis ▿

doi: 10.1128/JCM.01371-10

Figure Lengend Snippet: Linearity of anti-PT IgA concentrations measured by ELISA kits and compared to expected values of reference preparations.

Article Snippet: Virotech , Pertussis Toxin IgG/IgA , PT , IgG/IgA , Arbitrary VE/ml , 5 , 1.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Molecular Oncology

Article Title: HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer

doi: 10.1002/1878-0261.12883

Figure Lengend Snippet: HSP90 pharmacological inhibition or HSP90α knockout increases the pro‐apoptotic and DNA damage effect of CDDP in Pt‐res TOV‐112D cells. (A) Apoptosis and necrosis evaluated by flow cytometry after Annexin V‐FITC and propidium iodide staining in TOV‐112D Pt‐res cl. 7 and (B) cl. 2 cells, untreated or treated for 48 h (upper panels) or 72 h (lower panels), with CDDP and/or ganetespib at IC 50 72 h doses of parental cells. (C) Western blot analysis of γH2AX, PARP1 and caspase 3 cleavage, BAX and BCL2 expression, in TOV‐112D Pt‐res pool 2 cells untreated or treated with CDDP and/or ganetespib at the doses indicated above. β‐Actin expression serves as loading control. Western blot quantification was performed by imagej software. (D) Apoptosis and necrosis evaluated by flow cytometry after Annexin V‐FITC and propidium iodide staining in TOV‐112D, TOV‐112D Pt‐res cl. 7 and in HSP90α knockout TOV‐112D Pt‐res KO#2 cells, untreated or treated for 48 or 72 h with CDDP at IC 50 72 h doses of parental cells.

Article Snippet: Primary antibodies were purchased as follows: HSP90 alpha 2G5.G3 (#SMC‐147) and HSP90 (total) 4F3.E8 (#SMC‐149) from StressMarq Biosciences (Victoria, BC, Canada); GRP75 (#3593), LMN A/C (#2032), ANXA1 (#3299), Bax (#2774), CASPASE 3 (#9662), cleaved PARP1 (Asp214; #5625), PARP1 (#9542), Bcl‐2 (#4223S) from Cell Signaling Technology (Leiden, Netherlands); VIM (ab 16700), prohibitin (PHB; ab55618), CALR (ab2907), heat‐shock cognate 71‐kDa protein (HSP7C; ab19136), PGK1 (ab67335), PRDX4 (ab15574) from Abcam (Cambridge, UK); GRP78 C‐20 (sc‐1051), EZR H‐276 (sc‐20773), β‐actin C4 (sc‐47778), and GAPDH (FL‐335) from Santa Cruz Biotechnology Inc., (Dallas, TX, USA); VINC (10C‐CR1199M1) from Fitzgerald (Acton, MA, USA); ɣH2AX (Ser139) clone JBW301 (#05‐636) from Millipore (Burlington, MA, USA); and heterogeneous nuclear ribonucleoprotein L (HNRPL; A303‐895A) from Bethyl (Montgomery, TX, USA).

Techniques: Inhibition, Knock-Out, Flow Cytometry, Staining, Western Blot, Expressing, Software

Journal: Molecular Oncology

Article Title: HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer

doi: 10.1002/1878-0261.12883

Figure Lengend Snippet: Potentiation of CDDP antitumor effect induced by ganetespib in vivo CDDP‐resistant TOV‐112D xenograft model. TOV‐112D Pt‐res pool 2 cells (5 × 10 6 ) were s.c. injected into NSG mice as described in . When tumors were established, mice (five/group) were treated once a week for two weeks, with CDDP (2.5 mg·kg −1 i.p.), ganetespib (GANE; 75 mg·kg −1 i.p.), both drugs in combination, or their respective vehicles (UNT). (A) Relative TV measured at prespecified time points (Means ± SEM). (B) TVs at cutoff when mice were sacrificed. Data are shown as means ± SEM. (C) Mice body weight as surrogate indicator of toxicity for in vivo experiment reported in A. Body weight was measured three times/week. (D) TGD, indicating the mean rate of tumor growth in the treatment groups relative to control untreated mice (see ). Statistically significant results calculated with one‐way ANOVA test are reported (* P < 0.05, ** P < 0.01, and *** P < 0.001). (E) Western blot analysis of γH2AX, cleaved PARP1, cleaved caspase 3, HSP90α, and total HSP90, in lysates from three representative xenograft tumor samples from each treatment group (see ). β‐Actin expression serves as loading control. Western blot quantification was performed by imagej software using the mean value of the three samples for each experimental group.

Article Snippet: Primary antibodies were purchased as follows: HSP90 alpha 2G5.G3 (#SMC‐147) and HSP90 (total) 4F3.E8 (#SMC‐149) from StressMarq Biosciences (Victoria, BC, Canada); GRP75 (#3593), LMN A/C (#2032), ANXA1 (#3299), Bax (#2774), CASPASE 3 (#9662), cleaved PARP1 (Asp214; #5625), PARP1 (#9542), Bcl‐2 (#4223S) from Cell Signaling Technology (Leiden, Netherlands); VIM (ab 16700), prohibitin (PHB; ab55618), CALR (ab2907), heat‐shock cognate 71‐kDa protein (HSP7C; ab19136), PGK1 (ab67335), PRDX4 (ab15574) from Abcam (Cambridge, UK); GRP78 C‐20 (sc‐1051), EZR H‐276 (sc‐20773), β‐actin C4 (sc‐47778), and GAPDH (FL‐335) from Santa Cruz Biotechnology Inc., (Dallas, TX, USA); VINC (10C‐CR1199M1) from Fitzgerald (Acton, MA, USA); ɣH2AX (Ser139) clone JBW301 (#05‐636) from Millipore (Burlington, MA, USA); and heterogeneous nuclear ribonucleoprotein L (HNRPL; A303‐895A) from Bethyl (Montgomery, TX, USA).

Techniques: In Vivo, Injection, Western Blot, Expressing, Software